Podcast Episodes
Back to SearchTo Get Better Cancer Drugs Faster, Is It Time for an “International FDA”?
From ASCO 2024
The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FD…
1 year, 9 months ago
”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas.
"Very Important" Myeloma Data: ASCO Highlights, Smold…
1 year, 9 months ago
Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center.
Durvalumab's Benefit in SCLC "Beyond What We M…
1 year, 9 months ago
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” Potential, Expert Says
From ASCO 2024
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says.
Dr. Robert Figlin speaks with…
1 year, 9 months ago
Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Suggest That”
From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center.
Should All Breast Cancer Patients…
1 year, 9 months ago
Oncologist Shortage “Has Gotten to the Crisis Level”
Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Canc…
1 year, 10 months ago
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the …
1 year, 11 months ago
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), …
2 years ago
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical…
2 years ago
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real mile…
2 years ago